<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR5">
 <label>5.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Finn</surname>
    <given-names>RS</given-names>
   </name>
   <name>
    <surname>Ryoo</surname>
    <given-names>BY</given-names>
   </name>
   <name>
    <surname>Merle</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Kudo</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Bouattour</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Lim</surname>
    <given-names>HY</given-names>
   </name>
   <name>
    <surname>Breder</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Edeline</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Chao</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Ogasawara</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Yau</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Garrido</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Chan</surname>
    <given-names>SL</given-names>
   </name>
   <name>
    <surname>Knox</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Daniele</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Ebbinghaus</surname>
    <given-names>SW</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Siegel</surname>
    <given-names>AB</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>AX</given-names>
   </name>
   <name>
    <surname>Cheng</surname>
    <given-names>AL</given-names>
   </name>
   <collab>on behalf of the KEYNOTE-240 investigators</collab>
  </person-group>
  <article-title>Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial</article-title>
  <source>J Clin Oncol</source>
  <year>2020</year>
  <volume>38</volume>
  <issue>3</issue>
  <fpage>193</fpage>
  <lpage>202</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.19.01307</pub-id>
  <?supplied-pmid 31790344?>
  <pub-id pub-id-type="pmid">31790344</pub-id>
 </element-citation>
</ref>
